For over a century, antivenoms have relied on serum extraction from animals — a process that’s costly, inconsistent, and limited to specific snake species. Today, advances in synthetic biology and antibody engineering are pointing toward a different future: a universal antivenom capable of neutralizing toxins across the world’s deadliest snakes. This session dives into the science and story behind this breakthrough — from the man who endured more than 200 bites to generate a unique immune response, to the researchers using those antibodies to design broad-spectrum, recombinant therapies. Together, they’re charting the path from survival experiment to programmable immunity.

TBD

TBD

TBD

Brain Computer Interfaces (BCIs) hold immense promise to help restore critical functions now for individuals with neurological conditions, severe speech impairments, and paralysis. Over the last thirty-five years, major advancements in artificial intelligence, brain mapping, and material sciences are laying the foundation for a future where BCI-enabled augmented experience is as common as accessing the internet or using a mobile phone. Join Paradromics CEO Matt Angle, PhD to discuss the latest on neurotechnology today, as well as expansive future BCI applications.

Join Stanford’s Le Cong for an immersive, hands-on masterclass exploring how CRISPR, genome engineering, and next-generation biological foundation models are converging to redefine programmable biology. This live workshop will walk attendees through CRISPR/GPT — an emerging class of AI-assisted editing frameworks that pair large biological language models with precise genome engineering tools to accelerate design, improve specificity, and unlock new editing modalities. Participants will step inside real CRISPR/GPT workflows to see how multimodal models interpret genomic context, predict repair outcomes, suggest optimized guide designs, and generate editing strategies for complex loci. Le Cong will demonstrate how AI-driven reasoning is beginning to streamline experimental planning, reduce screening burden, and push forward new frontiers in base editing, prime editing, and programmable gene modulation. This session is designed for scientists, engineers, founders, and R&D leaders who want to understand how AI-powered CRISPR design actually works in practice — and how these tools can accelerate therapeutic development, functional genomics, and next-generation editing technologies.

check if we can move to another day

free for pow bio?

For 20+ years, the synthetic biology community has generated breakthrough targets, but too many continue to stall at the same choke points: freedom-to-operate, productivity, process robustness, CMC readiness, and the leap from “works in the lab” to “works at scale.” In this lightning talk, Ingenza will share how we’ve repeatedly helped teams cross that valley of death, turning innovative discoveries into manufacturable realities across industrial biotech and therapeutics. We’ll spotlight our inGenius® platform: a proven panel of high-performing microbial and mammalian production hosts paired with AI/ML-driven enzyme discovery and gene design optimisation (codABLE®), scalable upstream and downstream platform process workflows, and a comprehensive suite of high-end analytical tools that accelerate and de-risk the path from early discovery to market readiness. Powered by 20+ years of successful delivery, expect rapid, real, case study driven lessons from the front lines: what fails most often, what fixes it fastest, and how to design with manufacturability from day one without slowing innovation. If you’re engineering biology to improve human health or the planet, this talk is your shortcut to faster timelines and better outcomes that help SynBio move at the speed it promises.

24/137

Join Boltz co-founder Gabriele Corso for an interactive, hands-on masterclass exploring how next-generation AI models are transforming molecular design, protein engineering, and therapeutic development. In this live workshop, attendees will step inside the Boltz platform to learn how structure-based generative modeling pipelines can be applied to real-world design challenges. Participants will see how AI-driven predictions are reshaping the drug discovery workflow — from identifying high-value molecular hits to optimizing binders, and therapeutic candidates. This session is designed for scientists, founders, and R&D leaders looking to understand how to actually use cutting-edge AI to accelerate biological innovation.

The PURE system, invented 25 years ago, established a fully reconstituted approach to cell-free protein synthesis. What began as a system to better understand translation has evolved into a versatile platform for engineering biology. This talk highlights how PURE-derived platforms such as PUREfrex® enable rapid prototyping, high-throughput screening, and AI/ML-driven optimization, accelerating synthetic biology and next-generation biologics development.

Meat is one of the world’s most complex biomanufacturing systems—and also one of its least optimized. For 12,000 years, we’ve cycled crops through animals to make meat. Drawing from his new book Meat, Bruce Friedrich contends that advances across science and engineering now make it possible to produce meat far more efficiently, which will reduce meat’s contribution to hunger, climate change, deforestation, antibiotic resistance, and pandemic risk. Most importantly for the success of alternative meats, these new technologies will also improve food security and add to GDP for the nations that lean in. It’s been exactly ten years since the first plant-based burgers were introduced and also exactly ten years since the first cultivated meat companies were incorporated. Bruce will reflect on how far we’ve come, how far we have to go, and what it's going to take to get there. Welcome to the next agricultural revolution—courtesy of science.

For decades, pharmaceutical supply chains were optimized for cost and scale, stretching across continents to source critical active ingredients. But fragility has made resilience a strategic imperative. Synthetic biology offers a new model: onshoring the production of essential APIs by programming cells to manufacture small molecules, peptides, and novel amino acids with precision and scalability. Instead of relying on distant chemical supply networks, biology becomes the factory—flexible, distributed, and programmable. This session explores how engineered microbes and directed evolution platforms are rebuilding pharma supply chains from the molecular level up, enabling secure, responsive, and locally anchored production of the medicines the world depends on.

Biotech is no longer behind the scenes—it’s on our shelves, in our homes, and part of our daily routines. From sustainable haircare to household cleaning, and high-performance materials, bio-based innovations are redefining everyday consumer experiences. This session explores what drives adoption, how brands communicate the value of biology, and why trust, transparency, and performance are key to building loyalty. Join us to hear from the companies making biology irresistible, accessible, and seamlessly integrated into daily life—and learn what it takes to create bio-products consumers truly love.

The next frontier of biology isn’t in predicting a single static protein structure, but in capturing how proteins move, fold, and interact across time and environments. This session explores how AI can illuminate protein conformations and dynamics, and extend those insights into virtual multi-cellular or tissue models. Experts will discuss the challenge of integrating heterogeneous datasets and instruments, and how breakthroughs in dynamic modeling could reshape drug design, disease understanding, and biomanufacturing. Can we build models that reflect the living, breathing complexity of biology—not just snapshots, but motion?

Scaling bio-based products requires integrated technical collaboration across strain engineering, fermentation, downstream processing, and analytics. Full-stack approaches—where startups, CDMOs, and platform technology providers align early on—can optimize yield, reduce variability, and lower cost of goods (COGS) at commercial scale. This session explores case studies of cross-company collaboration, from co-development of microbial strains and bioreactor designs to shared process analytics and predictive modeling. Hear how teams are breaking down technical silos to accelerate scale-up, improve reproducibility, and create competitive, sustainable manufacturing solutions that bring synthetic biology products from the lab to the market efficiently.

Food is no longer just sustenance—it’s becoming a programmable interface with human biology. Advances in synthetic biology and foodtech are enabling the design of bioactive molecules that target specific health outcomes: regulating glucose and lipid metabolism, strengthening cardiovascular resilience, and even enhancing cognitive performance. From engineered microbes that secrete beneficial metabolites to programmable synbiotics tuned to the gut, this session will explore how programmable biology is transforming food into a therapeutic platform. Panelists will ask: what if the next breakthroughs in managing obesity, dementia, and heart disease don’t come from pharmaceuticals, but from intelligently designed foods and functional ingredients?

TBD

TBD

TBD

For decades, DNA synthesis has been the limiting reagent in synthetic biology — reliable for short sequences, but increasingly error-prone and costly as designs scale past 10kb. That ceiling is now cracking. New enzymatic synthesis platforms, error-correction chemistries, and assembly pipelines are extending what’s possible, opening the door to rapid construction of full pathways, microbial genomes, and even mammalian chromosomes. This session will explore how innovators are breaking past the 10kb barrier, what technical and economic breakthroughs are needed next, and how longer, cheaper, and faster synthesis could fundamentally change how we design biology at scale.

AI-enabled, self-driving labs are still emerging, but their foundations are already transforming how teams design, run, and interpret experiments. This session offers a practical guide for scientists and R&D leaders who want to understand what can be done today — from tightening design–test–learn loops to reducing manual error and capturing early benefits of autonomous experimentation. Rather than presenting an unrealized future, speakers will focus on practical, real-world steps that give organizations a competitive edge as SDL capabilities evolve and mature. Speakers will explore what’s working, what’s not, and how autonomous lab systems are reshaping protein engineering, pathway optimization, and therapeutic design.

Biology is entering an era where AI agents don’t just analyze data — they co-design, plan, and execute experiments. Multi-agent systems like CRISPR-GPT demonstrate how AI can act as a true lab co-pilot: decomposing complex genome editing projects into stepwise workflows, selecting tools, troubleshooting, and even drafting protocols that allow junior researchers to perform sophisticated edits on their first attempt . Beyond CRISPR, new systems like BioMARS integrate reasoning agents with robotics, while biotech companies are testing “AI lab assistants” that monitor and adjust experiments in real time. This session explores how multi-agent copilots are making biology more reproducible, democratizing complex workflows, and pushing the boundaries of lab autonomy. The central question: when AI can plan, troubleshoot, and validate experiments end-to-end, how should scientists and institutions govern this new power?

Mining has long relied on brute force and chemistry, but biology is opening a new frontier. Biomining uses engineered microbes to extract metals and minerals with precision, efficiency, and far less environmental impact than traditional methods. From rare earth elements essential to clean energy to critical metals powering electronics, synthetic biology is reshaping how we source the building blocks of modern life. This session spotlights innovators designing bio-based recovery systems, scaling sustainable solutions, and reimagining resource extraction.

Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.

Scaling bio-based products to commercial production requires balancing technical readiness with market and financial realities. This session examines the capital investments, regulatory planning, and supply chain strategies necessary to move beyond the pilot stage. Experts will share lessons on aligning production capacity with demand forecasts, managing operational risk, and structuring partnerships that unlock funding and market access. Attendees will gain practical insights into navigating investor expectations, scaling efficiently without compromising quality, and making strategic decisions that ensure products can succeed commercially while meeting evolving market needs and sustainability goals.

DRAFT SCHMIDT SCIENCES: Standard bioreactors often lack the instrumentation required to rapidly monitor cell physiology, leaving critical gaps in our understanding of scale-up dynamics. This session presents active projects from the Schmidt Sciences’ Sensors for Biomanufacturing Program designed to address this challenge through novel sensing modalities. Spanning from near real-time intracellular measurements to non-invasive off-gas fingerprinting, the panel brings together technology developers and industrial bioprocess experts to discuss the translation of these tools from the lab to the plant floor. Together, we will critically evaluate the utility of high-dimensional metabolic data and explore the engineering requirements for integrating physics-based sensors and machine learning into existing biomanufacturing workflows.

As biology becomes programmable and AI accelerates discovery, startups are generating breakthrough innovations at unprecedented speed. Yet translating these advances into real-world therapies still depends on effective collaboration with global pharmaceutical organizations. This session explores how the innovation ecosystem connects early-stage breakthroughs to scalable development, bringing together leaders from startup incubation, external innovation, and pharma strategy. Speakers will examine how AI-native biotech companies engage with pharma today: how startups become “pharma-ready,” how external innovation teams evaluate and structure partnerships, and what collaboration models are emerging as biology and computation converge. From early ecosystem support and venture building to strategic alliances and co-development pathways, the discussion will provide a practical look at how ideas move from discovery to patient impact in the AI era.

Industrial biotech faces repeated “valleys of death” between laboratory success and commercial manufacturing, driven by a combination of technological uncertainty, scale-dependent constraints, and (mis)alignment between engineering reality and investment expectations. Promising technologies often fail not because the science is wrong, but because scale-up trajectories are built on insufficient data, optimistic assumptions, and decision-making based on the 1st product specifications from the lab that do not translate to industrial conditions. This panel returns to fundamentals, drawing on real-world experience from piloting, process engineering, and early industrialization to examine where and why scale-up breaks down. Experts will discuss how important the scale-up journey is to align technology performance with investor expectations, support sound business cases, and turn the industrial biotech toolbox into a more robust, scalable, and profitable manufacturing platform.

TBD

The Design–Build–Test–Learn (DBTL) cycle remains the core engine of biological engineering, yet its iteration speed still lags far behind software development. As AI systems begin to design, plan, and execute experiments, a new paradigm is emerging: DBTL as an autonomous, continuously optimizing system. Next-generation platforms combine AI-assisted rational design, high-throughput construction and perturbation, real-time data acquisition, and active learning to close the loop at unprecedented scale. Agent-powered lab-in-a-loop workflows, lab-on-a-chip systems, and advances at the silicon-to-carbon interface are enabling tighter integration between computation and biology, from semiconductor-enabled sensing to real-time feedback and decision-making. This session explores how autonomous DBTL stacks could unlock software-like iteration velocity in biology, redefine experimentation, and reshape the future of programmable discovery.

Venture capital alone is no longer enough to power the next wave of biotechnology innovation. Across health, biosecurity, climate, and advanced biomanufacturing, government agencies are emerging as catalytic partners, deploying billions in non-dilutive funding to accelerate high-risk, high-impact breakthroughs. But accessing this capital requires more than strong science. Founders must understand how agencies like ARPA-H, DARPA, BARDA, and others evaluate risk, define mission impact, and structure partnerships that bridge research and real-world deployment. This session brings together agency leaders, founders, and experienced operators to demystify how government funding actually works in today’s market. The panelists will explore how startups can position themselves for success, avoid common pitfalls in proposal development and contracting, and strategically leverage non-dilutive funding to extend runway, de-risk technology, and unlock new commercial pathways.

As AI, automation, and scalable biotechnologies accelerate the design and deployment of biology, the line between innovation and risk is increasingly blurred. This session explores how advances in programmable biology are reshaping biosecurity and biodefense, from dual-use risks and supply-chain vulnerabilities to new models for detection, governance, and defense. Leaders from industry, government, and research will discuss how to responsibly accelerate biology while protecting public health and national security.

(Ivan to reach out)

TBD

For the first time, AI is enabling us to imagine medicines that “think” — turning on only inside diseased cells or under specific physiological conditions. This session explores how neural networks, trained on RNA and protein data, are unlocking programmable therapies with unprecedented precision. Imagine cancer drugs that remain inert until they meet tumor markers, or RNA vaccines that adapt to evolving viral landscapes in real time. The future of medicine isn’t static molecules — it’s intelligent, adaptive therapeutics

DRAFT: For more than a century, everyday products - from detergents and shampoos to textiles and packaging - have relied on petrochemicals and harsh industrial processes. Today, AI-driven protein design is opening a radically different path: creating custom enzymes and biomolecules that outperform traditional chemistry while reducing environmental impact. This session explores how advances in computational protein design and machine learning are enabling the rational creation of enzymes tailored for home care, personal care, and next-generation materials. Instead of screening nature for incremental improvements, scientists can now design proteins from first principles - optimizing stability, specificity, and performance for real-world industrial conditions.

This talk will introduce the development of artificial Agents to model biological phenomena in molecular biology, biotechnology, and synthetic biology incorporating reinforcement learning, differential equation modeling of molecular dynamics, and agentic bio-causal reasoning. Agent to agent interaction with the A2A and PoR protocols, and MCP and API interfaces to Machine Learning (Neural Network) Models including causal reasoning models and bio-specific models will be discussed. Synthetic biology deals with huge possibility spaces in terms of the combinatorics of nuceotide and proteomic sequences in proposed novel genes and proteins and how to constrain possibility spaces into computable functional novel genes, genetic circuits, gene regulatory networks and novel functional proteins will be discussed. Hence the sheer complexity of biological phenomena requires advanced Agentic AI and machine learning models to efficiently process, find patterns in, and reason about these complex systems with hundreds of thousands of variables, millions of connections, and potentially trillions of parameters. The current state of Agentic Bio research will be covered and where the research needs to go will be elucidated. Finally an application of Agentic Inter and Intra-cellular Signaling will be presented in detail to see the nuts and bolts of how Agentic AI can model a biological phenomenon with molecular biological, medical, and synthetic biological applications. The presenter’s background includes advanced degrees in computer science and computational molecular biology with experience in bio-computational modeling including a computational neuroscience project at Stanford where the neurogenetic and synaptic development of the C.elegans’ brain was modeled. Synthetic Biology: the possibility spaces are endless!

Once viewed as reckless experimentation, germline gene editing is re-emerging as a serious scientific frontier. With base and prime editing now able to correct single-letter mutations with remarkable precision, researchers are beginning to demonstrate embryo edits that could one day eliminate devastating inherited diseases. The stakes, however, are profound: these are permanent, heritable changes passed to every future generation. This session examines the cutting edge of germline engineering—how far the science has advanced since CRISPR’s clumsy early days, what challenges remain around mosaicism and long-term safety, and where the ethical boundaries must be drawn. Should we consider germline editing only for rare, fatal conditions when no other reproductive options exist? Or is there a pathway to broader medical use under strict safeguards? Join leading scientists, ethicists, and policymakers as we debate whether rewriting inheritance is an act of compassion—or a step too far.

Instrumentation remains one of the greatest bottlenecks in bioinnovation. For decades, meaningful progress required billion-dollar facilities and industrial-scale reactors. Today, that paradigm is shifting. Emerging tools — from smart shake flasks and modular bioreactors to microfluidic systems, desktop DNA printers, and next-generation sequencing devices — are flipping the economics of scale.

From tissues morphing in development to microbes competing in a bioreactor, biology is inherently emergent. Multi-agent simulations — from platforms like BioDynaMo, CompuCell3D, and BIO-LGCA — are now powerful enough to model billions of interacting agents, capturing diffusion, metabolism, migration, and signaling with physical fidelity. Synthetic biologists are using these frameworks to probe design limits before moving to the lab, asking questions like: How far can diffusion alone carry a signaling molecule? What metabolic bottlenecks emerge in crowded cells? And how do engineered traits play out at population scale? This session will spotlight how agent-based models are becoming essential design environments for synthetic biology, helping teams test hypotheses virtually, anticipate failure modes, and translate biology into an engineering discipline rooted in predictive, quantitative simulation.

"Reading, writing, and editing DNA were just the prelude. The new frontier is composition—designing entire genomes like symphonies, guided by AI models trained on millions of sequences. In this new paradigm, biology becomes a writable medium where genes, circuits, and chromosomes are arranged with intention rather than discovered by chance. From AI-optimized CRISPR systems and compact editors like TIGR to CRISPR SWAPnDROP and Bridge Recombinases capable of megabase-scale rewrites in human cells, a new toolkit is emerging that treats the genome not as a fragile molecule but as an editable architecture. These molecular instruments bypass the cell’s own repair machinery, offering a level of precision and predictability that brings genome design closer to true composition—a craft as deliberate and creative as writing code or composing music.

T cells are no longer just killers. They are becoming fully programmable platforms that sense, compute, remember, and act inside the body. From next generation CAR and TCR therapies to in vivo reprogramming and AI designed receptors, a new wave of technologies is turning T cells into living software that can be updated, networked, and deployed against cancer, autoimmunity, infection, and beyond.This session brings together pioneers at the intersection of synthetic biology, immunology, and AI who are building the next generation of T cell therapies. We will explore how genome scale datasets, structural models, and large biological foundation models are transforming TCR and CAR design. We will dive into logic circuits, synNotch systems, and control layers that let T cells sense combinations of signals, avoid exhaustion, and adapt inside solid tumors. And we will ask the hard questions about safety, durability, manufacturability, and access as T cell engineering moves from bespoke autologous products to off the shelf and in vivo editing strategies.

Biology is entering an AI-driven era, but most experimental infrastructure still produces data designed for individual experiments, not for learning at scale. As a result, much of today’s data is useful in the moment but poorly suited for training robust, long-lived models. This session will explore what biological data matters most today, what data needs to be generated now to support future models, and how leading teams are closing that gap. Panelists will discuss how automation, metadata discipline, and standardized testing pipelines can turn artisanal lab workflows into continuous experiment-to-learning systems. The focus will be on infrastructure and experimental design, highlighting practical bottlenecks, emerging best practices, and what becomes possible when biology produces abundant, high-quality, model-ready data by default.

Enzymes are becoming the precision tools behind cleaner, more efficient, and more sustainable production across both home-care and food manufacturing. In cleaning products, next-generation enzymes replace harsh chemicals with biodegradable, high-performance biocatalysts that work at lower temperatures and deliver superior stain, odor, and grease removal. In food processing, engineered proteases, lipases, amylases, and fiber-modifying enzymes are unlocking new textures, cleaner labels, better stability, and reduced energy use—reshaping how everything from dairy and bakery to beverages and plant proteins are made.

Plant-based food sales may be slowing, but that doesn’t mean innovation on the plate is stalling. Instead, momentum is shifting toward breakthrough technologies and smarter ingredient combinations. Cultured meat and precision fermentation are driving the next wave of sustainable ingredients, from proteins to cultured fats that bring authentic flavor and texture. This session highlights advances in cell culture, fermentation platforms, and scale-up strategies, along with the partnerships moving products from R&D to dining tables. Hear how food innovators are combining biology and culinary creativity to build a resilient, delicious, and sustainable future for global diets.

What happens when AI systems stop being tools and begin acting like collaborators in scientific thought? Multi-agent architectures such as SciAgents and Google’s “AI Co-Scientist” are pioneering hypothesis generation by dividing scientific reasoning into specialized sub-agents: literature retrievers, causal mappers, and graph-based reasoners. Unlike single models, these teams of agents mimic the structure of scientific collaboration itself — brainstorming, critiquing, and refining ideas. In synthetic biology, such systems could propose new gene circuits, uncover hidden regulatory logic, or suggest underexplored protein folds. This session asks: how far should we trust AI-generated hypotheses, and how do we validate them responsibly? With machine-driven insight now on the horizon, the very architecture of discovery may shift — from lone researchers and teams of humans to networks of humans and machines co-creating the future of biology.

Despite major advances in the biology of aging, there are still no interventions that clearly slow or reverse aging in humans. In contrast, modern medicine already depends on replacement to restore lost function, from artificial joints and cardiac devices to organ transplants and stem cell therapies. This session examines how a similar framework could be applied to aging: rather than repairing deteriorated cells and tissues, scientists and companies are exploring ways to replace them with newly generated, biologically young equivalents. The discussion will highlight emerging capabilities in engineered cell sources, scalable tissue fabrication, and programmable biology (instead of "integration") strategies that are redefining what can be rebuilt and replaced. New approaches are beginning to address long-standing challenges such as age-related signaling environments, vascularization, and even circuit compatibility in parts of the brain. Together, these advances point toward a future where rejuvenation is achieved through deliberate biological reconstruction. The session asks: How far can replacement take us, and could rebuilding youthful parts become a central path to extending healthy lifespan?

Industrial biology has moved through clear phases. First-generation leaders like Novozymes and ADM built durable businesses on fermentation expertise, process control, and long-term customer contracts. The second wave, including Amyris, Zymergen, and Twist Bioscience, emphasized platform modularity and scientific acceleration, but often scaled ahead of sustained product pull. As capital markets tightened, many of those models were stress-tested. This session explores what a third generation looks like: demand-led, capital disciplined, and grounded in real manufacturing capability. Rather than building brands or speculative platforms, Gen 3 companies start with urgent problems inside large enterprises such as Mars, Nestlé, and Unilever, develop minimum testable products with modest initial investment, and scale only with validated offtake and operational readiness. We will discuss portfolio-style R&D, customer co-development, global manufacturing realities, and the operator mindset required to build resilient industrial bio companies in today’s environment.

How can local communities benefit from biotechnology? This session explores strategies for building decentralized biotech ecosystems that support local innovation, shared ownership, and resilient bioeconomies. By aligning biotechnology with planetary stewardship and place-based knowledge, we highlight a new era of bio-based products and initiatives led by founders bringing their culture and community into biotechnology.

As the U.S. accelerates into the age of biotechnology, the future of our national competitiveness, economic growth, and security depend on a workforce and citizenry fluent in biotechnology. This panel brings together leaders to explore how bioliteracy and a biotech-ready workforce can become strategic assets to power the U.S. bioeconomy.

Traditional chemical synthesis often suffers from long routes, poor selectivity, and high environmental impact, while conventional biosynthesis is constrained by evolutionary path dependency. The integration of de novo (0→1) enzyme development dramatically expands the accessible synthetic space. Key advantages include significantly shortened synthetic pathways, liberation from natural evolutionary constraints, and the creation of entirely novel intellectual property. In this discussion, we will outline the implementation strategy of this integrated biosynthetic paradigm and present several case studies demonstrating its successful application within our company

TBD

Climate volatility is reshaping the future of food, demanding crops that can withstand heat, drought, and disease. Synthetic biology offers powerful tools to accelerate adaptation—engineering plants with traits that once took decades to breed. This session explores how innovators are designing resilient crops, building platforms for rapid trait development, and forging collaborations across agtech, biotech, multinationals, and policy. Join us to hear how synbio is moving beyond the lab to the field, reshaping agriculture for resilience, and ensuring farmers worldwide can thrive in the face of climate uncertainty.

IDEA: Invitation to the last round of BO + invite for the rave (closure ceremony at [details...])

Synthetic biology has long offererd vibrant pigments and functional ingredients with consistency, scalability, and improved sustainability. While many US policy shifts are creating headwinds for biotech innovation, the regulatory momentum around food colors and ingredients could open a significant opportunity for synbio adoption. This session examines the opportunities and risks ahead, highlighting how innovators can align with shifting rules, build trust, and bring bio-based ingredients from lab to label in a rapidly evolving food landscape.

Cell-free systems are redefining what’s possible in bioproduction. By bypassing the complexity of living cells, innovators can run enzyme cascades, prototype metabolic pathways, and produce high-value molecules with unmatched speed, precision, and purity. This new class of systems—from freeze-dried reactions to continuous cell-free reactors—enables rapid iteration, on-demand production, and scalable biochemistry without the need for fermentation tanks or long development cycles.

Batch fermentation built modern biotech, but it is increasingly the constraint. As the industry pushes for higher productivity, lower costs, and more sustainable inputs, two alternatives are emerging as front-runners: continuous fermentation and gas fermentation. This session puts them head-to-head. Where does continuous fermentation win on control and throughput? Where does gas fermentation outperform on feedstock flexibility and carbon efficiency? And which approach is most likely to scale reliably outside the lab? Leaders from both camps debate what it really takes to move beyond batch—and which platform is best positioned to win.

Mitochondria are often pigeon-holed as the "powerhouse of the cell", giving the false impression that their primary role is as an ATP generator passively responding to the energetic demands of their environment. This is far from the truth. The mitochondria exist as a dynamic network that senses, integrates, and transduces biochemical, energetic, and physical signals, and these signals shape cell fate, lifespan, cancer risk, and more. This session explores emerging tools and methods to edit the small, maternally-inherited, circular mitochondrial genome present in dozens-to-hundreds of copies per cell as a means to prevent mitochondrial disease and optimize metabolic fitness. Additionally, we will discuss the promise of mitochondrial transplantation methodologies as a therapeutic intervention and to discuss the possible routes for mitochondrial metabolic engineering and a range of synthetic developments.

AI is reshaping how biopharma discovers and engineers therapeutic proteins. But with dozens of platforms and models emerging, R&D leaders face a strategic crossroads: should they build internal AI capabilities, buy turnkey software, or partner with platforms that integrate computational design and wet-lab validation? This session brings together pharma R&D executives and AI platform leaders to explore how software-first, closed-loop AI workflows are transforming the speed, success rate, and economics of biologics development. Speakers will share real-world outcomes—from 12× faster lead optimization to multiparameter protein design pipelines that integrate seamlessly into existing discovery organizations.

A mission to Mars is as much a biomedical challenge as it is an engineering one. Microgravity, radiation, immune dysfunction, and limited medical infrastructure transform routine health risks into mission-critical threats. Survival on another planet will depend on our ability to predict, monitor, and treat disease far from Earth. This session explores how bioengineering is tackling NASA’s biggest human health risks: bioregenerative life-support systems that recycle essential resources, human organoids that model physiology in space, computational tools to decode complex omics data in real time, compact sequencing and onboard analysis platforms that shrink the lab to spacecraft scale, and novel pharmacologic strategies designed for deep-space missions. On the journey to Mars, medicine won’t just travel with astronauts — it will be engineered alongside them.

Biology innovation is becoming both more global and more fragmented at the same time. As synthetic biology, AI-driven drug discovery, and biomanufacturing scale worldwide, nations and companies are simultaneously competing for technological leadership while relying on cross-border collaboration to accelerate discovery. Export controls, data governance, regional funding strategies, and national bioeconomy agendas are reshaping how partnerships form, yet science, talent, and innovation networks remain deeply interconnected. This session explores how the global biology ecosystem is evolving beyond traditional geopolitics. Leaders from industry, startups, academia, and investment will examine how collaboration and competition coexist across the US, Europe, China, and emerging innovation hubs.

Cells are often described as bags of chemistry—but they are better understood as finely tuned physical systems. Within each one, DNA is packed into nanoscopic volumes, enzymes race at turnover rates rivaling jet engines, and molecular collisions happen billions of times per second. This session explores the cell as a physical object—its limits of size, speed, and efficiency. How fast can information move from genome to protein? How does diffusion constrain cell size and shape? How do energy flows through metabolism define what life can and cannot do? By examining the physics that underpins biology, this session challenges us to see cells not as mysterious black boxes, but as programmable systems operating under universal rules. This perspective may hold the key to engineering biology with the same rigor as physics and computer science.

The SBB Bio Beats: DJ After Party brings the science of sound to the dancefloor. Research suggests that music and audible vibrations can influence cellular growth and behavior, reminding us that biology responds to rhythm, synchronizing with our biological code.. Starting at 8pm, this high energy celebration marks a playful conclusion to the SynBioBeta Programmable Biology Conference, blending house beats with the spirit of our global community. Step away from the sessions, connect with fellow innovators, and share an atmosphere of joy and celebration where sound, movement, and biology meet. Join the party, feel the pulse, and let the rhythm connect our community on a deeper level.